Effects of vibegron on ambulatory blood pressure in patients with overactive bladder: results from a double-blind, placebo-controlled trial

OBJECTIVES: To characterize the blood pressure (BP) profile of the new β(3)-adrenergic receptor agonist, vibegron, in patients with overactive bladder. METHODS: Patients were randomized to once-daily vibegron 75 mg or placebo for 28 days and underwent ambulatory BP monitoring. The primary endpoint w...

Descripción completa

Detalles Bibliográficos
Autores principales: Weber, Michael A., Haag-Molkenteller, Cornelia, King, Jennifer, Walker, Ann, Mudd, Paul N., White, William B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Devices and Technology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8893125/
https://www.ncbi.nlm.nih.gov/pubmed/34699409
http://dx.doi.org/10.1097/MBP.0000000000000572

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8893125/
https://www.ncbi.nlm.nih.gov/pubmed/34699409
http://dx.doi.org/10.1097/MBP.0000000000000572

Ejemplares similares